On June 19, two stories from different ends of the PFAS research pipeline converged in The Guardian, and together they paint a stark picture of the burden these “forever chemicals” place on human health.
The first story is about a community in Lancashire living in the shadow of a factory that released 49 tonnes of the PFAS chemical PFOA into the air over more than six decades. The second is a Harvard-led study showing that prenatal exposure to certain PFAS chemicals is associated with a more than doubling of the odds that a daughter will later develop PMOS, the newly renamed condition formerly known as Polycystic Ovary Syndrome. One story is about past emissions and current cancer rates; the other is about a chain of cause and effect that begins before birth.
The factory: 49 tonnes of PFOA over Blackpool
AGC Chemicals Europe Ltd, based at the Hillhouse Technology Enterprise Zone in Thornton-Cleveleys, Lancashire (just north of Blackpool), manufactured PFOA (perfluorooctanoic acid) used in production of PTFE (polytetrafluoroethylene) non-stick coatings from the 1950s until 2012. During that period, approximately 49 tonnes of PFOA were released into the atmosphere. PFOA was classified as carcinogenic to humans by the International Agency for Research on Cancer in 2023, and has been globally banned under the Stockholm Convention since 2020.
A multi-agency “Health Cell” convened by the Director of Public Health of Lancashire County Council, including the UK Health Security Agency, NHS Lancashire and South Cumbria, the National Disease Registration Service, and the Environment Agency, analyzed kidney cancer incidence patterns in small census areas (LSOAs) within a 5 km radius of the factory over the period 2003-2022.
The report, published May 12, 2026, found that most cancers were not elevated overall. But two LSOAs stood out. In LSOA E01025596 (southeast of the site in Thornton), there were 14 observed kidney cancer cases versus 6 expected, a Standardized Incidence Ratio of 218 (95% CI: 119-367). In LSOA E01012665 (north Blackpool), there were 17 observed cases versus 9 expected, an SIR of 181 (95% CI: 106-290).
The official conclusion: “No statistically significant excess kidney cancer cases; no evidence of a cluster; no further cluster investigation is warranted at this stage.”
Several independent experts pushed back. Dr. David Megson, a forensic environmental scientist at Manchester Metropolitan University, called the conclusion “very contradictory,” noting that the data show a “discernible rise” in kidney cancer near the factory. Dr. Dan Middleton of Queen’s University Belfast, an expert in environmental cancer epidemiology, said the results “should not be dismissed outright” and called blood testing of local residents the “missing link” in determining whether PFOA is responsible. Dr. Tony Fletcher, a PFAS epidemiology specialist at the London School of Hygiene and Tropical Medicine, described a “slight increase” consistent with a small PFOA-related risk.
The Environment Agency has advised residents within one kilometer of the factory not to consume fruit, vegetables, or eggs from gardens and allotments. An allotment adjacent to the factory has been shut down and classified as contaminated land under Part 2A of the Environmental Protection Act 1990. The law firm Leigh Day is investigating legal claims on behalf of affected residents.
The study: PFAS before birth, PMOS decades later
Meanwhile, the same day brought news of a study connecting PFAS exposure at a different point in the life cycle altogether. Researchers at Harvard T.H. Chan School of Public Health, led by Dr. Zifan Wang and senior investigator Dr. Shruthi Mahalingaiah, published findings in Environmental Research linking maternal PFAS concentrations during pregnancy to the development of Polyendocrine Metabolic Ovarian Syndrome (PMOS) in daughters later in life.
PMOS is the new name for what was previously called Polycystic Ovary Syndrome (PCOS), adopted following a May 2026 consensus statement in The Lancet led by Professor Helena Teede of Monash University. The condition affects approximately 13 percent of women globally, roughly 170 million people, and is characterized by irregular menstrual cycles, elevated androgen levels, metabolic dysfunction, and increased risk of infertility and mental health disorders.
The Harvard study drew on 322 mother-daughter pairs from Project Viva, a Boston-area pre-birth cohort that enrolled pregnancies between 1999 and 2002. Maternal blood plasma was collected at a median of 9.6 weeks gestation and analyzed for six PFAS compounds.
The results were striking for two specific chemicals. For daughters whose mothers had double the concentration of EtFOSAA (2-(N-ethyl-perfluorooctane sulfonamido) acetate) in early pregnancy, the adjusted odds of developing PMOS were 2.66 times higher (95% CI: 1.18-5.99). For PFNA (perfluorononanoate), maternal doubling was associated with 2.33 times higher odds of moderate-to-severe acne (95% CI: 1.09-4.99), a core symptom of PMOS. No significant association was found for the PFAS mixture as a whole, meaning the signal was driven by specific compounds rather than PFAS exposure in aggregate.
This is the first study to specifically assess prenatal PFAS exposure and the subsequent development of PMOS years later. Previous research had linked PFAS chemicals to hormonal and metabolic disruption, but the prenatal window, when the developing reproductive and endocrine systems may be especially vulnerable, had not been examined for this particular outcome.
Two stories, one chemistry
The Lancashire factory released PFOA. The Harvard study found signals from EtFOSAA and PFNA. But the two stories speak to the same underlying problem: PFAS chemicals are extraordinarily persistent in the environment and in the body, they do not break down naturally, and their health effects are still being catalogued.
PFOA emitted from a factory in the 1950s remains measurable in the soil, water, and bodies of people living nearby today. PFNA and EtFOSAA, used in industrial and consumer products for decades, pass from mother to fetus across the placenta. The latency period for cancer can be decades; the latency period for reproductive endocrine effects can span from gestation to adulthood.
“The study suggests that exposure to ‘forever chemicals’ may be a main driver of disease,” Wang said, as reported by The Guardian.
The two stories illustrate that PFAS contamination has no single geography or timeline. It moves through air, water, soil, and the placenta. And it makes its mark not in one dramatic event, but in the slow accumulation of elevated risks, in an industrial town in Lancashire, and in mothers and daughters living hundreds of miles from any factory.
Disclosure: The Lancashire Health Cell report (12 May 2026) is a multi-agency public health assessment, not a peer-reviewed study. The Harvard study in Environmental Research (Volume 268, Article 120786) is peer-reviewed.
Sources:
- Guardian: “Kidney cancer rates near PFAS factory in Lancashire a ‘major source of concern'” (19 June 2026). Link
- Guardian: “New research links prenatal exposure to PFAS to later development of PMOS” (19 June 2026). Link
- Wang, Z. et al. (2025). “Associations of maternal per- and polyfluoroalkyl substance plasma concentrations during pregnancy with offspring polycystic ovary syndrome and related characteristics in Project Viva.” Environmental Research, 268, 120786. DOI: 10.1016/j.envres.2025.120786
- Lancashire County Council Health Cell Report (12 May 2026). Link